August 16, 2022 – GSK completes acquisition of Affinivax, Inc. READ MORE >
Affinivax is a clinical stage biopharmaceutical company with a next generation vaccine technology platform called the Multiple Antigen Presentation System (MAPS). MAPS uses a patented approach to achieve high-affinity binding of two key immunogenic components – polysaccharide and protein antigens – so that both components are able to drive a broad and protective B-cell and T-cell immune response in a single vaccine. We believe the result is a significant step forward in vaccine technology, creating novel preventive and therapeutic vaccines targeting resistant infectious and other immune-mediated diseases.
Trade marks are owned by or licensed to the GSK group of companies.
©2022 GSK group of companies or its licensor.
This links to an external website.